The aim of this study was to assess which prognostic factors could influence survival in surgically treated stage IA non-small cell lung cancer. The records of 224 consecutive patients with pathological stage IA after radical surgery were reviewed retrospectively. Overall 1, 3 and 5-year survival rates were 89%, 76%, and 66%. Nearly half of the deaths were unrelated to the original cancer. There was no difference in survival attributable to preoperative pulmonary function, age at operation, or extent of resection. However, patients with limited resections had a higher rate of local recurrence. Survival was better with a smaller size of tumor (= 2 cm), in the female sex, and in cases of bronchoalveolar adenocarcinoma.
Get full access to this article
View all access options for this article.
References
1.
MountainCF. Revisions in the International System for Staging Lung Cancer. Chest1997; 111: 1710–7.
2.
MartiniNBainsMSBurtMEZakowskiMFMcCormackPRuschVW. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg1995; 109: 120–9.
3.
NesbittJCPutnamJBJrWalshGLRothJAMountainCF. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg1995; 60: 466–72.
4.
D'AmicoTAAloiaTAMooreMBHerndonJE2ndBrooksKRLauCL. Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg2000; 69: 882–6.
5.
OhtaYTomitaYOdaMWatanabeSMurakamiSWatanabeY. Tumor angiogenesis and recurrence in stage I non-small cell lung cancer. Ann Thorac Surg1999; 68: 1034–8.
6.
FeldRRubinsteinLThomasPA. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group. J Natl Cancer Inst1993; 85: 299–306.
7.
LittleAGDeMeesterTRFergusonMKSkinnerDBHoffmanPCSkoseyC. Modified stage I (T1N0M0, T2N0M0), nonsmall cell lung cancer: treatment results, recurrence patterns, and adjuvant immunotherapy. Surgery1986; 100: 621–8.
8.
ImmermanSCVaneckoRMFryWAHeadLRShieldsTW. Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. Ann Thorac Surg1981; 32: 23–7.
9.
BreatnachOSKwiatkowskiDJFinkelsteinDMGodleskiJSugarbakerDJJohnsonBE. Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease. J Thorac Cardiovasc Surg2001; 121: 42–7.
10.
RenaOPapaliaERuffiniECasadioCFilossoPLOliaroA. Stage I pure bronchioloalveolar carcinoma: recurrences, survival and comparison with adenocarcinoma of the lung. Eur J Cardio-thorac Surg2003; 23: 409–14.
11.
OkadaMYoshikawaKHattaTTsubotaN. Is segmentectomy with lymph node assessment an alternative to lobectomy for non-small cell lung cancer of 2 cm or smaller?Ann Thorac Surg2001; 71: 956–60.
12.
WarrenWHFaberLP. Segmentectomy versus lobectomy in patients with stage I pulmonary carcinoma: five-year survival and patterns of intrathoracic recurrence. J Thorac Cardiovasc Surg1994; 107: 1087–94.
13.
AlexiouCOnyeakaCVPBeggsDAkarRBeggsLSalamaFD. Do women live longer following lung resection for carcinoma?Eur J Cardio-thorac Surg2002; 21: 319–25.
14.
SakaoYSakuragiTNatsuakiMItohT. Clinicopathological analysis of prognostic factors in clinical IA peripheral adenocarcinoma of the lung. Ann Thorac Surg2003; 75: 1113–7.
15.
BoydCAThurezRSLoCiceroJIIIHubermanMBoisellePWatsonA. Is it time to subdivide T1 lesions in resected non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol2000; 20: 310a.
16.
YanagiSSugiuraHMorikawaTKajiMOkushibaSKondoS. Tumor size does not have prognostic significance in stage IA NSCLC. Anticancer Res2000; 20: 1155–8.
17.
MottaGCarboneESpinelliENahumMATestaTFlocchiniGP. Considerations about tumor size as a factor of prognosis in NSCLC. Ann Ital Chir1999; 70: 893–7.
PatzEFJrRossiSHarpoleDHJrHerndonJEGoodmanPC. Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. Chest2000; 117: 1568–71.
20.
GajraANewmanNGambleGPAbrahamNZKohmanLJGrazianoSL. Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease. Lung Cancer2003; 42: 51–7.
